SWOT Analysis
Strength:
- Increasing research and development activities for developing effective therapeutics is expected to drive the market growth. Several clinical trials are being conducted to evaluate drug candidates.
- Rising awareness regarding primary sclerosing cholangitis is positively impacting the market. Various non-profit organizations are conducting awareness programs.
- Availability of various treatment options such as medications, endoscopic procedures, and liver transplantation provide hope to patients.
Weakness:
- Lack of approved drugs for effective treatment of primary sclerosing cholangitis poses a major challenge. Existing treatment options only manage symptoms.
- High costs associated with liver transplantation limits its widespread adoption in developing regions.
Opportunity:
- Emerging economies presents lucrative growth opportunities owing to increasing healthcare expenditure and large patient population base.
- Ongoing research on developing biomarker-based diagnostic tests is expected to expedite the diagnosis process.
Threats:
- Chronic nature of the disease affects treatment compliance and dropout rates from clinical trials.
- Stringent regulatory process for drug approval delays market accessibility of new treatment options.
Key Takeaways
The Global Primary Sclerosing Cholangitis Market Size is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing research funding initiatives for developing novel therapeutics.
Regional analysis
North America dominated the global market in 2022 and is expected to maintain its lead over the forecast period. This is attributed to growing PSC patient pool coupled with presence of major players in the region. Asia Pacific is anticipated to be the fastest growing market due to rising healthcare expenditure, increase in disease awareness levels.
Key players
Key players operating in the primary sclerosing cholangitis market are Dr. Falk Pharma, Intercept Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Takeda Pharmaceutical, HighTide Therapeutics. Dr. Falk Pharma leads the market and has established its Ursodeoxycholic acid capsule brands for PSC symptom management globally.
Cerca
Categorie
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Giochi
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Altre informazioni
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology
Leggi tutto
Pricing Analysis and Profitability Models in the Asia-Pacific Olive Oil Market: Factors Impacting Market Competitiveness
Asia-Pacific olive oil market coupled with the growing application of olive oil in...
Common mistakes with ISO 13485 Certification in France documentation control and how to avoid them
IN ISO 13485 Certification in France the Documentation control is the primary task for...
Process Spectroscopy Market Size, Competitive Landscape 2023
The global process spectroscopy market size was valued at USD 18,058.0 million in 2022 and is...
classic,,<<<$>>>,,https://www.24x7hls.com/provacan-premium-cbd/
Provacan Gold CBD Oil Spray UK :- For positive, Provacan Premium Gold CBD Oil Spray UK is gotten...